Skip to Content
Merck

565730

Sigma-Aldrich

Scriptaid

A relatively non-toxic, cell-permeable hydroxamic acid-containing histone deacetylase (HDAC) inhibitor.

Synonym(s):

Scriptaid, 6-(1,3-Dioxo-1 H,3 H-benzo[ de]isoquinolin-2-yl)-hexanoic Acid Hydroxyamide, CGK1026, HDAC Inhibitor XIII, 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic Acid Hydroxyamide, CGK1026, HDAC Inhibitor XIII

Sign Into View Organizational & Contract Pricing

Select a Size



About This Item

Empirical Formula (Hill Notation):
C18H18N2O4
CAS Number:
Molecular Weight:
326.35
UNSPSC Code:
12352200

Quality Level

Assay

≥95% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

off-white

solubility

DMSO: 4 mg/mL

shipped in

ambient

storage temp.

−20°C

InChI

1S/C18H18N2O4/c21-15(19-24)10-2-1-3-11-20-17(22)13-8-4-6-12-7-5-9-14(16(12)13)18(20)23/h4-9,24H,1-3,10-11H2,(H,19,21)

InChI key

JTDYUFSDZATMKU-UHFFFAOYSA-N

General description

A relatively non-toxic hydroxamic acid-containing histone deacetylase (HDAC) inhibitor. Facilitates transcriptional activation (TGFβ/Smad4) in both stable and transient reporter assays in a concentration-dependent manner. Useful agent for transfection assays in reporter systems due to the lack of interference with the ability of reporter construct to measure positive activation of transcription factor in response to signal transduction stimulus. It causes over 100-fold increase in histone acetylation in PANC-1 cells at 2 µg/ml (6 µM). Reported to derepress hTERT by inhibiting the recruitment of HDAC into E2F-pocket protein complexes assembled on the hTERT promoter.
A relatively non-toxic, cell-permeable hydroxamic acid-containing histone deacetylase (HDAC) inhibitor. Facilitates transcriptional activation (TGFβ/Smad4) in both stable and transient receptor assays in a concentration-dependent manner. At ~2 µg/ml (6-8 µM) concentrations, results in a greater than 100-fold increase in histone acetylation in PANC-1 cells. Reported to derepress hTERT by inhibiting the recruitment of HDAC into E2F-pocket protein complexes assembled on the hTERT promoter.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
HDAC
Product does not compete with ATP.
Reversible: no

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Won, J., et al. 2004. Proc. Natl. Acad. Sci. USA101, 11328.
Su, G.H., et al. 2000. Cancer Res.60, 3137.

Legal Information

Sold under license of U.S. Patent 6,544,957.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Related Content

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service